TY - JOUR
T1 - Suppression effect on IFN-γ of adipose tissue-derived mesenchymal stem cells isolated from β2-microglobulin-deficient mice
AU - Masuda, Junko
AU - Takayama, Eiji
AU - Ichinohe, Tatsuo
AU - Strober, Warren
AU - Mizuno-Kamiya, Masako
AU - Ikawa, Tomokatsu
AU - Kitani, Atsushi
AU - Kawaki, Harumi
AU - Fuss, Ivan
AU - Kawamoto, Hiroshi
AU - Seno, Akimasa
AU - Vaidyanath, Arun
AU - Umemura, Naoki
AU - Mizutani, Akifumi
AU - Kasai, Tomonari
AU - Honjo, Yasuko
AU - Satoh, Ayano
AU - Murakami, Hiroshi
AU - Katsura, Yoshimoto
AU - Kondoh, Nobuo
AU - Seno, Masaharu
N1 - Publisher Copyright:
© 2018, Spandidos Publications. All rights reserved.
PY - 2018/11
Y1 - 2018/11
N2 - Administration of bone marrow-derived mesenchymal stem cells (MSCs) is a possible treatment for graft-versus-host disease (GVHD) following allogeneic hematopoietic stem cell transplantation and other inflammatory conditions. To address the mechanism of immunosuppression by MSCs, in particular those derived from adipose tissue (AMSCs), AMSCs were isolated from three different mouse strains, and the suppressive capacity of the AMSCs thus obtained to suppress interferon (IFN)-γ generation in mixed lymphocyte reaction cultures serving as an in vitro model of GVHD were assessed. It was revealed that the AMSCs had a potent capacity to suppress IFN-γ production regardless of their strain of origin and that such suppression was not associated with production of interleukin-10. In addition, the results demonstrated that β2-microglobulin (β2m)-deficient AMSCs from β2m-/- mice were also potent suppressor cells, verifying the fact that the mechanism underlying the suppression by AMSCs is independent of major histocompatibility complex (MHC) class I expression or MHC compatibility. As AMSCs appear to have immunosuppressive properties, AMSCs may be a useful source of biological suppressor cells for the control of GVHD in humans.
AB - Administration of bone marrow-derived mesenchymal stem cells (MSCs) is a possible treatment for graft-versus-host disease (GVHD) following allogeneic hematopoietic stem cell transplantation and other inflammatory conditions. To address the mechanism of immunosuppression by MSCs, in particular those derived from adipose tissue (AMSCs), AMSCs were isolated from three different mouse strains, and the suppressive capacity of the AMSCs thus obtained to suppress interferon (IFN)-γ generation in mixed lymphocyte reaction cultures serving as an in vitro model of GVHD were assessed. It was revealed that the AMSCs had a potent capacity to suppress IFN-γ production regardless of their strain of origin and that such suppression was not associated with production of interleukin-10. In addition, the results demonstrated that β2-microglobulin (β2m)-deficient AMSCs from β2m-/- mice were also potent suppressor cells, verifying the fact that the mechanism underlying the suppression by AMSCs is independent of major histocompatibility complex (MHC) class I expression or MHC compatibility. As AMSCs appear to have immunosuppressive properties, AMSCs may be a useful source of biological suppressor cells for the control of GVHD in humans.
KW - Adipose tissue-derived mesenchymal stem cells
KW - Graft vs. host disease
KW - Major histocompatibility complex class I
KW - β2-microglobulin
UR - http://www.scopus.com/inward/record.url?scp=85053854159&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053854159&partnerID=8YFLogxK
U2 - 10.3892/etm.2018.6689
DO - 10.3892/etm.2018.6689
M3 - Article
AN - SCOPUS:85053854159
SN - 1792-0981
VL - 16
SP - 4277
EP - 4282
JO - Experimental and Therapeutic Medicine
JF - Experimental and Therapeutic Medicine
IS - 5
ER -